Nasus Pharma LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
AMEX
NSRX
Nasus Pharma LTDNasus Pharma reports positive Phase 2 clinical results for its intranasal Epinephrine candidate, NS002, and successfully raises $15 million in a private placement, despite continued operating losses and going concern doubts.